NCI-H1650Homo sapiens (Human)Cancer cell line

Also known as: NCIH1650, H1650_CO, H-1650, H1650

🤖 AI SummaryBased on 14 publications

Quick Overview

Human lung cancer cell line with known mutations and drug resistance profiles.

Detailed Summary

The NCI-H1650 cell line is a human lung cancer cell line derived from a non-small cell lung carcinoma. It is commonly used in research to study the molecular mechanisms of cancer progression and drug resistance. This cell line has been characterized for its response to various therapeutic agents, including EGFR inhibitors, and has been shown to develop resistance through specific genetic alterations. The cell line is also utilized in studies related to cell signaling pathways and tumor biology. Research on NCI-H1650 has contributed to understanding the role of EGFR mutations in cancer treatment and the development of targeted therapies.

Research Applications

Cancer biologyDrug resistance mechanismsEGFR signalingTumor progression

Key Characteristics

EGFR mutation statusDrug resistance profilesCell signaling pathways
Generated on 6/17/2025

Basic Information

Database IDCVCL_1483
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age27
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseMinimally invasive lung adenocarcinoma
LineageLung
SubtypeNon-Small Cell Lung Cancer
OncoTree CodeNSCLC

DepMap Information

Source TypeATCC
Source IDACH-000035_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53c.673-2A>G (IVS6-2A>G)UnspecifiedSplice acceptor mutationfrom parent cell line KYSE-30
MutationSimpleEGFRp.Glu746_Ala750del (c.2235_2249del15)Unspecified-from parent cell line PC-9

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D10S1248
13
D12S391
22
D13S317
11
D16S539
11,12
D18S51
10
D19S433
15
D1S1656
15,15.3
D21S11
30
D22S1045
11
D2S1338
19
D2S441
10
D3S1358
18
D5S818
11
D7S820
8,9
D8S1179
12
FGA
20
Penta D
8
Penta E
12
TH01
9.3
TPOX
11
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Proteomic and ultrastructural analysis of Clara cell and type II alveolar epithelial cell-type lung cancer cells.

Hou W.-L., Chang M., Liu X.-F., Hu L.-S., Hua S.-C.

Transl. Cancer Res. 9:565-576(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.

Jimenez C.R.

J. Proteomics 196:106-119(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.

Ghosh G., Lian X.-J., Kron S.J., Palecek S.P.

BMC Cancer 12:95.1-95.14(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Takada M., Fukuoka M., Nakagawa K.

Cancer Res. 67:2046-2053(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources